Horizon Therapeutics Public Limited Company Financials

Market Capitalization $26.63 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	61.86
Forward PE	20.55
Price to Sales TTM	$7.34
Price to Book MRQ	$5.01
Enterprise to Revenue	7.40
Enterprise to EBITDA	24.08

Financial Reports as of Jun. 30, 2023

Financials

Fiscal Year Ends	2022-12-31
Most Recent Quarter	2023-06-30
Profit Margin	74.64%
Operating Margin	16.83%
Return on Assets TTM	5.72%
Return on Equity TTM	10.28%

Income Statement

Revenue TTM	$3,629,044,000
Revenue per Share TTM	$15.84
Quarterly Revenue Growth	13.57%
Gross Profit TTM	$2,708,847,000
EBITDA	$957,027,000
Net Income to Common TTM	$521,482,000
Diluted EPS TTM	$2.22
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$0
Total Cash per Share MRQ	$
Total Debt MRQ	$
Total Debt to Equity MRQ	0.48
Current Ratio MRQ	4.27
Book Value per Share MRQ	$23.22

Cash Flow

Operating Cash Flow TTM	$1,327,918,000
Levered Free Cash Flow TTM	$1,807,718,000

HZNP Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	228,995,008
Float Shares	None
Avg 10 Volume	16,742,430
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	%
% Held by Institutions	%

Stock Price Summary

Beta
Fifty Two Week Low	$116.30
Fifty Two Week High	$116.34
Fifty Two Week Change	0.00%
Day 50 MA	$0.00
Day 200 MA	$0.00

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$
Trailing Annual Dividend Yield	%
Payout Ratio	%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date